Toll-like receptor 1 (TLR1) often designated as CD281 (cluster of differentiation 281), a member of the Toll-like receptor family recognizes pathogen-associated molecular pattern with specificity for gram-positive bacteria.
Toll-like receptor 1 (TLR1) often
designated as CD281 (cluster
of differentiation 281), a
member of the Toll-like receptor family recognizes pathogen-associated
molecular pattern with specificity for gram-positive bacteria. TLR1 is
a 786-residue type I transmembrane protein with a 581-amino acid
leucine-rich extracellular domain (ECD), a 23-amino acid transmembrane domain
(amino acids 582 to 604), and a 181-amino acid cytoplasmic Toll
homology signalling domain (1, 2). TLR1 maps to chromosome 4p14 with
a calculated molecular weight of 84 kDa (3, 4). TLR1 is most closely related to
TLR6 and TLR10 with 68% and 48% overall amino acid sequence identity,
respectively. Among members of the TLR family, TLR1 along with TLR6 comprise
the most highly conserved pair and appear to have arisen more
recently during evolution through a gene duplication event. Different length
transcripts presumably resulting from use of alternative polyadenylation site,
and/or from alternative splicing, have been noted for TLR4.
In vivo, two different sized
transcripts for TLR1 are observed suggesting that the mRNA is alternatively
spliced to generate two different forms of the protein. TLR1 mRNA is ubiquitously expressed and found
at higher levels than the other TLRs. Of the major leukocyte populations, TLR1
is most highly expressed by monocytes, but is also expressed by macrophages,
dendritic cells (DCs), polymorphonuclear leukocytes, B, T, and NK cells. While
TLR1 expression is most significantly upregulated by autocrine IL-6, it is also
elevated by IFN-γß, IL-10, and TNF-α. However, TLR1 level is unaffected by
exposure to both Gram-positive and Gram-negative bacteria.
TLR1 along with TLR6 functions as
a co-receptor for TLR2, which confers ligand specificity and enables
cell signaling. Collectively, these receptor pairs mediate immune
responses to a wide variety of acylated cell wall components derived
from Gram-positive bacteria, Gram-negative bacteria, mycoplasma,
spirochetes, and fungi. TLR1 also heterodimerizes with TLR4, not to enhance its
function, but to inhibit TLR4 activity (5, 6). Defects in the TLR1/2 signaling
pathway may account for human hyporesponsiveness to OspA vaccination.
Through the reciprocal exchange
of extracellular domains between the human TLRs 1 and 6, it has been
revealed that TLR1/2 and TLR2/6 receptor pairs exhibit different
specificities toward many microbial agonists including diacylated
and triacylated lipopeptides, which is determined by the region comprised of
leucine-rich repeat motifs 9–12 of these receptors. A recent finding suggests
that three nonsynonymous single nucleotide polymorphisms (SNPs) are
located in this region of TLR1. A variant of TLR1 based upon the SNP
P315L, located in the loop of LRR motif 11 (LRR11), is greatly
impaired in mediating responses to lipopeptides. The P315L SNP may
predispose certain individuals to infectious diseases for which the
sensing of microbial cell components by TLR1 is critical to innate
immune defense (7). Thus variation in the inflammatory response to bacterial
lipopeptides is regulated by a common TLR1 transmembrane domain polymorphism
that could potentially impact the innate immune response and clinical
susceptibility to a wide spectrum of pathogens.
Reference:
1. Janeway, C. A., Jr, R. Medzhitov. 2002. Innate immune recognition. Annu. Rev.
Immunol. 20: 197-216.
2. Takeda, K., T. Kaisho, S. Akira. 2003. Toll-like
receptors. Annu. Rev.
Immunol. 21: 335-376.
3.Beutler, B., Z.
Jiang, P. Georgel, K. Crozat, B. Croker, S. Rutschmann, X. Du, K. Hoebe. 2006.
Genetic analysis of host resistance: Toll-like receptor signaling and immunity
at large. Annu.
Rev. Immunol. 24: 353-389.
4. Rock, F.L. et
al. (1998) Proc. Natl. Acad.
Sci. USA 95:588.
5. Ozinsky, A. et
al. (2000) Proc. Natl. Acad. Sci. USA 97:13766.
6. Wyllie, D.H. et al. (2000) J. Immunol. 165:7125.
7. Katherine O. Omueti The Journal of Immunology, 2007, 178:
6387-6394.
| Additional articles about Toll-like receptors |
|
|
| About the author |
IMGENEX India Pvt Ltd. the only biotech company in Orissa and one of its kinds in Eastern India. IMGENEX India started in Oct as an outsourcing branch of IMGENEX Corporation, San Diego, USA. Find out more information about Toll-like receptors .
|
| Please Rate This Article |
Number of ratings: 0
Rating: 0